An update on the current and emerging targeted agents in metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 11, Issue 1, 2012, Pages 1-13

  Chu, Edward ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Anti EGFR inhibitors; Anti VEGF inhibitors; Colorectal tumors; Drug development; Fibroblast growth factor; Phase III clinical trials; Small molecules; Targeted biologic agents

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFATINIB; AFLIBERCEPT; AXITINIB; BEVACIZUMAB; BMS 908662; BRIVANIB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; CONATUMUMAB; DALOTUZUMAB; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GANITUMAB; ICRUCUMAB; IRINOTECAN; LINIFANIB; NECITUMUMAB; NINTEDANIB; OXALIPLATIN; PANITUMUMAB; PEGDINETANIB; PERIFOSINE; PLEXIKON; RAMUCIRUMAB; REGORAFENIB; RILOTUMUMAB; SELUMETINIB; SORAFENIB; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLEEDING; BLOOD VESSEL PERMEABILITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE PROGRESSION; CHEMOSENSITIVITY; COLORECTAL CANCER; COMPETITIVE INHIBITION; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MONOTHERAPY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS; TUMOR VOLUME;

EID: 84861539889     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.05.005     Document Type: Review

References (90)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
2. Comella P, Casaretti R, Sandomenico C, et al. Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence. Drugs 2008; 68:949-61.
3. de Gramont A, Louvet C, Andre T, et al. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Eur J Cancer 1998; 34:619-26.
4. Capdevila J, Elez E, Peralta S, et al. Oxaliplatin-based chemotherapy in the management of colorectal cancer. Expert Rev Anticancer Ther 2008; 8:1223-36.
5. Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev 2006; 32:491-503.
6. Blick SK, Scott LJ. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 2007; 67:2585-607.
7. Keating GM. Panitumumab: a review of its use in metastatic colorectal cancer. Drugs 2010; 70:1059-78.
8. McCormack PL, Keam SJ. Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs 2008; 68:487-506.
9. Gallagher DJ, Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology 2010; 78:237-48.
10. Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005; 23: 7125-34.
11. Saif MW, Chu E. Biology of colorectal cancer. Cancer J 2010; 16:196-201.
12. Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J Clin Oncol 2010; 28:4045-51.
13. Todaro M, Francipane MG, Medema JP, et al. Colon cancer stem cells: promise of targeted therapy. Gastroenterology 2010; 138:2151-62.
14. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997; 132:541-6.
15. Ellis LM, Takahashi Y, Liu W, et al. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 2000; 5(suppl 1): 11-5.
16. Takahashi Y, Kitadai Y, Bucana CD, et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55:3964-8.
17. Fan F, Wey JS, McCarty MF, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005; 24: 2647-53.
18. Epstein RJ. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev 2007; 26:443-52.
19. Medical News Today Web site. Pfizer Discontinues Phase 3 Trial of Sutent in Metastatic Colorectal Cancer. Available at: http://www.medicalnewstoday.com/ articles/156079.php. Accessed December 14, 2010.
20. AstraZeneca Web site. AstraZeneca Announces Results of Recentin HORIZON II Phase III Trial in Metastatic Colorectal Cancer. Available at: http://www.astrazeneca.com/Media/Press-releases/Article/20100528-AstraZeneca- Announces-Resultsof-Recentin-HORIZON-II-. Accessed November 23, 2010.
21. Koehne C, Bajetta E, Lin E, et al. Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIMR 2) [abstract]. J Clin Oncol 2006; 24(18 suppl):abstract 3508.
22. Tabernero J, Aranda E, Gomez A, et al. Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): the MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]) [abstract]. J Clin Oncol 2010; 28(15 suppl):abstract 3501.
23. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
24. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 2007; 25:4779-86.
25. Sobrero A, Ackland S, Clarke S, et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 2009; 77:113-9.
26. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20:1842-7.
27. Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009; 14:862-70.
28. Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010; 28:453-9.
29. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013-9.
30. Stathopoulos GP, Batziou C, Trafalis D, et al. Chemotherapy with or without bevacizumab in advanced colorectal cancer: a phase III trial. Presented at: the 35th European Society for Medical Oncology (ESMO) Congress; October 8-12, 2010; Milan, Italy. Abstract 606P.
31. de Gramont A, Buyse M, Abrahantes JC, et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 2007; 25:3224-9.
32. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009; 43:490-501.
33. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab, J Clin Oncol 2011; 29:632-8.
34. Veronese ML, O'Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 2004; 40:1292-301.
35. Zhang W, Gordon M, Lenz HJ. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann Med 2006; 38:545-51.
36. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009; 283:125-34.
37. Clinicaltrials.gov [Website]. ASPECCT: a study of panitumumab efficacy and safety compared to cetuximab in subjects with KRAS wild-type metastatic colorectal cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01001377? term-NCT01001377&rank-1. Accessed November 30, 2010.
38. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658-64.
39. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
40. Souglakos J, Kalykaki A, Vamvakas L, et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 2007; 18:305-10.
41. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327:293-7.
42. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304:1812-20.
43. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27:663-71.
44. Markman B, Javier RF, Capdevila J, et al. EGFR and KRAS in colorectal cancer. Adv Clin Chem 2010; 51:71-119.
45. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11:753-62.
46. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408-17.
47. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28:4697-705.
48. Maughan TS, Adams R, Smith CG.MRCCOIN Trial Investigators. Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): mature results of the MRC COIN trial [abstract]. J Clin Oncol 2010; 28(15 suppl): abstract 3502.
49. Hasskarl J. Sorafenib. Recent Results Cancer Res 2010; 184:61-70.
50. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-19.
51. Prenen H, Tejpar S, Van Cutsem E. New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin Cancer Res 2010; 16:2921-6.
52. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27:672-80.
53. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360:563-72.
54. Clinicaltrials.gov [Website]. Cetuximab and/or bevacizumab combined with combination chemotherapy in treating patients with metastatic colorectal cancer (CALGB/SWOG 80405). Available at: http://clinicaltrials.gov/ct2/show/ NCT00265850?term-NCT00265850&rank-1. Accessed November 30, 2010.
55. Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 2009; 9:263-71.
56. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002; 99:11393-8.
57. Frischer JS, Huang J, Serur A, et al. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. Int J Oncol 2004; 25:549-53.
58. Fukasawa M, Korc M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res 2004; 10:3327-32.
59. Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A 2003; 100:7785-90.
60. Kadenhe-Chiweshe A, Papa J, McCrudden KW, et al. Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol Cancer Res 2008; 6:1-9.
61. Jin K, Shen Y, He K, et al. Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer? Clin Transl Oncol 2010; 12:526-32.
62. Clinicaltrials.gov [Website]. Aflibercept versus placebo in combination with irinotecan and 5-FU in the treatment of patients with metastatic colorectal cancer after failure of an oxaliplatin based regimen (VELOUR). Available at: http://clinicaltrials.gov/ct2/show/NCT00561470?term-NCT00561470&rank-1. Accessed November 30, 2010.
63. Clinicaltrials.gov [Website]. Study of aflibercept and modified folfox6 as first-line treatment in patients with metastatic colorectal cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00851084?term-NCT00851084&rank-1. Accessed November 30,2010.
64. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28:780-7.
65. Spratlin JL, Mulder KE, Mackey JR. Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol 2010; 6:1085-94.
66. Clinicaltrials.gov [Website]. A study in second line metastatic colorectal cancer. Available at: http://clinicaltrials.gov/ct2/results?term- NCT01183780. Accessed December 13, 2010.
67. Clinicaltrials.gov [Website]. Irinotecan hydrochloride and cetuximab with or without ramucirumab in treating patients with advanced colorectal cancer with progressive disease after treatment with bevacizumab-containing chemotherapy. Available at: http://clinicaltrials.gov/ct2/show/NCT01079780?term- NCT01079780&rank-1. Accessed December 13, 2010.
68. Schwartz JD, Rowinsky EK, Youssoufian H, et al. Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (human antibody targeting vascular endothelial growth factor receptor-1). Cancer 2010; 116(4 suppl):1027-32.
69. Clinicaltrials.gov [Website]. A study of IMC-1121B or IMC-18F1 in colorectal cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01111604? term-NCT01111604&rank-1. Accessed November 30, 2010.
70. Kies MS, Blumenschein GR Jr, Christensen O, et al. Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2010; 28(15 suppl):abstract 7585.
71. Shimizu T, Tolcher AW, Patnaik A, et al. Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors [abstract]. J Clin Oncol 2010; 28(15 suppl):abstract 3035.
72. Clinicaltrials.gov [Website]. Patients with metastatic colorectal cancer treated with regorafenib or placebo after failure of standard therapy. Available at: http://clinicaltrials.gov/ct2/show/NCT01103323?term-NCT01103323&rank-1. Accessed November 30, 2010.
73. Christensen O, Buechert M, Fasol U, et al. Analysis of plasma biomarkers, DCEMRI, and K-RAS mutations in patients with advanced colorectal carcinoma treated with the multikinase inhibitor regorafenib. Presented at: The 35th European Society for Medical Oncology (ESMO) Congress; October 8-12, 2010; Milan, Italy.
74. Jeffers M, Quinn DI, Joensuu H, et al. Identification of plasma biomarkers for the multikinase inhibitor regorafenib (BAY 73-4506) in patients (pts) with renal cell cancer (RCC). The 35th European Society for Medical Oncology (ESMO) Congress; October 8-12, 2010.
75. Cai ZW, Zhang Y, Borzilleri RM, et al. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f] [1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 2008; 51:1976-80.
76. Huynh H, Ngo VC, Fargnoli J, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008; 14:6146-53.
77. Ayers M. Comparison of a dual inhibitor of VEGF and FGF signaling, BMS-582664, to the activity of bevacizumab, an inhibitor exclusively of VEGF signaling, in xenograft models of colon carcinoma [abstract]. AACR Meeting Abstracts 2007;April 2007:1618.
78. Garrett C, Siu L, El-Khoueiry A, et al. A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy [abstract]. J Clin Oncol 2008; 26(15 suppl):abstract 4111.
79. Ayers M, Awad M, Malone D, et al. Association of K-ras status with efficacy end points from a phase 1/2 study of brivanib in combination with cetuximab in patients with advanced or metastatic colorectal cancer (CRC). Presented at: American Society of Clinical Oncology Gastrointestinal Cancers (ASCO-GI) Symposium; January 15-17, 2009; San Francisco, CA. Abstract 375.
80. Park YS, El-Khoueiry A, Cubillo A, et al. A blinded placebo (P) controlled phase 1/2 dose escalation study (DES) of brivanib (B), an oral selective dual inhibitor of FGF and VEGF signaling, in combination with cetuximab (C) and irinotecan (I). Presented at: The 35th European Society for Medical Oncology (ESMO) Congress; October 8-12, 2010; Milan, Italy.
81. Clinicaltrials.gov [Website]. Cetuximab with or without brivanib in treating patients with metastatic colorectal cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00640471?term-NCT00640471&rank-1. Accessed November 30, 2010.
82. Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009; 11:102-10.
83. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010; 16:34-44.
84. Clinicaltrials.gov [Website]. Placebo-controlled study of perifosine single agent chemotherapy for metastatic cancer patients. Available at: http://clinicaltrials.gov/ct2/show/NCT00398879?term-NCT00398879&rank-1. Accessed December 13, 2010.
85. Vukelja S, Richards D, Campos LT, et al. Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with secondor third-line metastatic colon cancer. [abstract]. J Clin Oncol 2009; 27(15 suppl): abstract 4081.
86. Clinicaltrials.gov [Website]. Perifosine plus capecitabine versus placebo plus capecitabine in patients with refractory advanced colorectal cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01097018?term- NCT01097018&rank-1. Accessed November 30, 2010.
87. Dierks C. GDC-0449-targeting the hedgehog signaling pathway. Recent Results Cancer Res 2010; 184:235-8.
88. Van Cutsem E, Eng C, Tabernero J, et al. A randomized phase I/II trial ofAMG102 or AMG 479 in combination with panitumumab (pmab) compared with pmab alone in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): safety and efficacy results. J Clin Oncol 2011; 29 (suppl 4);abstract 366.
89. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009; 86:97-100.
90. Printz C. BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery. Cancer 2010; 116: 3307-8.